Glaukos' Epioxa NDA Accepted by FDA for Keratoconus Treatment
核心洞察
Glaukos (搜索) announced FDA acceptance of its New Drug Application (NDA) for Epioxa (搜索), a novel therapy for keratoconus (搜索).
Epioxa (搜索) is a next-generation, non-invasive corneal cross-linking therapy designed to strengthen corneal tissue.
The FDA has set a PDUFA goal date of October 20, 2025, for the completion of its review of the Epioxa (搜索) NDA.
Glaukos (搜索) Corporation's New Drug Application (NDA) for Epioxa (搜索) has been accepted by the U.S. Food and Drug Administration (FDA), marking a significant step toward a potential new treatment option for keratoconus (搜索). Epioxa, a next-generation corneal cross-linking therapy, is designed to halt the progression of this sight-threatening condition.
Epioxa: A Novel Approach to Keratoconus Treatment
Epioxa (搜索) represents a potential advancement in keratoconus (搜索) therapy. Thomas Burns, Glaukos (搜索) chairman and chief executive officer, stated that Epioxa could be the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium. This is a key differentiator from existing treatments, potentially reducing procedure times, improving patient comfort, and shortening recovery time.
Clinical Trial Data and Efficacy
The NDA submission includes data from two Phase 3 pivotal trials. Both trials successfully achieved their pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles. One study showed a clinically meaningful and statistically significant improvement in maximum corneal curvature (Kmax) at 12 months compared to the sham/placebo-controlled arm. Specifically, 91.5% of patients in the treatment group completed the 12-month trial, compared to 90.9% in the control group.
Keratoconus: Disease Burden and Current Treatments
Keratoconus (搜索) is characterized by progressive thinning and weakening of the cornea, often diagnosed in a patient’s teenage years. If left untreated, it can lead to vision loss and is a leading cause of corneal transplants in the United States. Approximately 90% of cases are bilateral, and up to 20% of patients may require a corneal transplant. While conventional treatments like eyeglasses or contact lenses manage symptoms, Glaukos (搜索)' first-generation iLink therapy, Photrexa, is the only FDA-approved therapy shown to slow or halt disease progression.
Mechanism of Action and Key Features of Epioxa
Epioxa (搜索) utilizes a novel drug formulation designed to penetrate the epithelial layer of the cornea, combined with a stronger UV-A irradiation protocol and supplemental oxygen to enhance cross-linking. This approach aims to strengthen corneal tissue and halt the progression of keratoconus (搜索) while preserving the corneal epithelium.
Regulatory Timeline and Future Prospects
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of October 20, 2025, for the completion of its review of the Epioxa (搜索) NDA, reflecting a standard 10-month review period. If approved, Epioxa could become the first non-invasive corneal cross-linking therapy available to patients, offering a significant advancement in the treatment of keratoconus (搜索).